SCHEMBL4755940

SCHEMBL4755940

NC(=O)c1cccc(C(=O)c2ccc3c(c2)/C(=C/Nc2ccc(N4CCOCC4)cc2)C(=O)N3)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.43
PDPK1 O15530 1/20 0.43
AKT2 P31751 2/20 0.42
ERBB2 P04626 1/20 0.41
RET P07949 1/20 0.41
CSF1R P07333 1/20 0.41
RORC P51449 1/20 0.40
TLK2 Q86UE8 1/20 0.39
STK4 Q13043 1/20 0.39
STK3 Q13188 1/20 0.39
LRRK2 Q5S007 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
SIRT3 Q9NTG7 1/20 0.39
MAPT P10636 1/20 0.39
ALOX12 P18054 1/20 0.39
RAB9A P51151 1/20 0.39
AURKB Q96GD4 1/20 0.38
RAF1 P04049 1/20 0.38
PAK1 Q13153 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569087 1.00 PDGFRB (0.43) PDGFRBPDPK1AKT2ERBB2RET
SCHEMBL3578295 0.94 CSF1R (0.47) PDGFRBERBB2RETCSF1RRORC
SCHEMBL3580559 0.94 PDGFRB (0.43) PDGFRBPDPK1AKT2ERBB2RET
SCHEMBL3569089 0.91 PDGFRB (0.43) PDGFRBAKT2ERBB2RETCSF1R
SCHEMBL3573216 0.90 PDPK1 (0.42) PDPK1AKT2RETCSF1RTLK2
SCHEMBL4758319 0.90 PDPK1 (0.42) PDPK1AKT2RETCSF1RTLK2
SCHEMBL3580563 0.88 PDGFRB (0.43) PDGFRBAKT2ERBB2RETCSF1R
SCHEMBL3573943 0.87 CSF1R (0.49) PDGFRBERBB2RETCSF1RMAPT
SCHEMBL3571619 0.87 JAK3 (0.46) PDGFRBPDPK1AKT2RETCSF1R
SCHEMBL3571618 0.87 JAK3 (0.46) PDGFRBPDPK1AKT2RETCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 PDGFRB 407/4885PDPK1 86/4885AKT2 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.